ALG6 Inhibitors
ALG6 inhibitors constitute a specialized group of chemical compounds designed to reduce the functional activity of the enzyme ALG6 through indirect interference with various glycosylation pathways. For instance, Swainsonine targets the Golgi alpha-mannosidase II, which is pivotal for the synthesis of N-linked oligosaccharides; the inhibition of this enzyme impedes the glycosylation process that is essential for the proper function of ALG6. Similarly, Castanospermine and Deoxynojirimycin interfere with glucosidases, whose activity is necessary for the correct trimming of glucose residues required for ALG6 substrate preparation, leading to a functional decrease of ALG6 activity. Deoxymannojirimycin and its analogs, such as 1-Deoxymannojirimycin (DMJ) and Ketanserin, specifically target mannosidase I, halting the maturation of N-linked glycans and thereby reducing the availability of substrates for ALG6, culminating in diminished enzymatic activity. Kifunensine also inhibits mannosidase I, further stressing the importance of this step in the modulation of ALG6 activity. Nonyl deoxynojirimycin extends this inhibition profile by targeting glucosidase enzymes, thus affecting the glycosylation pathway upstream of ALG6.
The reduction of ALG6 activity extends with the use of CVT-313, which, by potently inhibiting glucosidases, alters the glycan precursor maturation process. Miglustat, though primarily a glucosylceramide synthase inhibitor, exhibits an off-target effect on glucosidases that similarly results in the downstream diminishment of ALG6 function by way of disrupted glycosylation. Lastly, Salbostatin, despite its primary bacterial target, shows potential for eukaryotic glucosidase inhibition, suggesting a secondary pathway through which ALG6 activity may be curtailed. Collectively, these chemical inhibitors converge on the crucial glycosylation process, either by limiting substrate availability or by blocking key enzymatic steps, to exert a collective inhibitory effect on ALG6, highlighting the intricacies of intracellular glycan processing and its impact on enzyme functionality.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $138.00 $251.00 $631.00 $815.00 $1832.00 | 6 | |
Swainsonine is an indolizidine alkaloid that acts as an inhibitor of Golgi alpha-mannosidase II, an enzyme involved in glycoprotein synthesis. By inhibiting this enzyme, the processing of N-linked oligosaccharides is disrupted, which indirectly diminishes the function of ALG6 by preventing its proper glycosylation. | ||||||
Castanospermine | 79831-76-8 | sc-201358 sc-201358A | 100 mg 500 mg | $184.00 $632.00 | 10 | |
Castanospermine is an indolizidine alkaloid that inhibits glucosidase enzymes. Glucosidase inhibitors prevent the trimming of glucose residues in the N-linked glycosylation pathway. This inhibition indirectly results in inadequate substrate availability for ALG6, leading to its functional diminishment. | ||||||
Deoxynojirimycin | 19130-96-2 | sc-201369 sc-201369A | 1 mg 5 mg | $73.00 $145.00 | ||
Deoxynojirimycin is an iminosugar that inhibits glucosidases. It hampers the initial steps of N-linked oligosaccharide processing, which is a prerequisite for ALG6 activity. Thus, the proper function of ALG6 is indirectly diminished by the upstream blockade of this pathway. | ||||||
Kifunensine | 109944-15-2 | sc-201364 sc-201364A sc-201364B sc-201364C | 1 mg 5 mg 10 mg 100 mg | $135.00 $540.00 $1025.00 $6248.00 | 25 | |
Kifunensine is a mannosidase I inhibitor that disrupts the formation of Man9GlcNAc2-PP-dolichol, the substrate for ALG6. The inhibition of this substrate formation leads to an indirect reduction in ALG6 functional activity by limiting its glycosylation capacity. | ||||||
Ketanserin | 74050-98-9 | sc-279249 | 1 g | $700.00 | ||
Ketanserin, a deoxymannojirimycin derivative, is a mannosidase inhibitor that interferes with N-glycan processing. The inhibition of this process indirectly diminishes ALG6 activity by disrupting the normal biosynthesis pathway of glycoproteins that require ALG6 for their maturation. | ||||||
CVT-313 | 199986-75-9 | sc-221445 sc-221445A sc-221445B | 1 mg 5 mg 50 mg | $104.00 $416.00 $2601.00 | 17 | |
CVT-313 is a potent glucosidase inhibitor. Its inhibitory action on the enzyme indirectly reduces ALG6 activity by altering the glycan precursor maturation, which is essential for the enzymatic function of ALG6 in the glycosylation pathway. | ||||||